V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 280008505 | 280005703 | 1.75 | 57 | Adjuvant (A) | 2018-02-28 | 2018-07-25 | EW Rel rEECur Irinotecan/Temozolomide | null | null | 280027820 | IRINOTECAN + TEMOZOLOMIDE |
| 280008506 | 280005705 | 1.59 | null | Neo-adjuvant (N) | 2013-02-19 | 2013-03-02 | Cyclophosphamide Weekly PO | N | N | 280027822 | CYCLOPHOSPHAMIDE |
| 280008507 | 280005706 | 1.65 | null | Palliative (P) | 2014-03-27 | 2014-05-02 | Doxorubicin + Ifosfamide | N | N | 280027833 | DOXORUBICIN + IFOSFAMIDE |
| 280008508 | 280005706 | 1.62 | 53.8 | Palliative (P) | 2017-12-30 | 2018-07-19 | VAI (Ifos 3g/m2) | N | N | 280027833 | IRINOTECAN + MDG |
| 280008509 | 280005706 | 1.64 | 106.4 | Neo-adjuvant (N) | 2014-02-01 | 2014-02-02 | Doxorubicin + Ifosfamide | 02 | N | 280027833 | DOXORUBICIN + IFOSFAMIDE |
| 280008510 | 280005708 | 1.7 | 90.2 | Curative (C) | 2017-03-03 | 2017-03-24 | Carboplatin + Paclitaxel (3 weekly) | 02 | N | 280027844 | CARBOPLATIN + PACLITAXEL |
| 280008511 | 280005709 | 1.58 | 61.6 | Palliative (P) | null | 2017-08-15 | Carboplatin + Paclitaxel (3 weekly) | null | null | 280027850 | CARBOPLATIN + PACLITAXEL |
| 280008512 | 280005711 | 1.75 | null | Curative (C) | 2017-11-24 | 2018-01-20 | Doxorubicin + Olaratumab | null | null | 280027851 | DOXORUBICIN + OLARATUMAB |
| 280008513 | 280010577 | 1.67 | 54.3 | Neo-adjuvant (N) | 2015-08-09 | 2015-09-20 | GEMCITABINE | 02 | N | 280027852 | GEMCITABINE |
| 280008514 | 280010577 | 1.49 | 58.6 | Adjuvant (A) | 2017-10-18 | 2018-06-23 | Doxorubicin + Ifosfamide | 2 | N | 280027852 | DOXORUBICIN + IFOSFAMIDE |
| 280008515 | 280005713 | null | null | Neo-adjuvant (N) | 2013-07-24 | 2013-08-01 | Doxorubicin + Ifosfamide | 02 | N | 280027853 | DOXORUBICIN + IFOSFAMIDE |
| 280008516 | 280005714 | 1.6 | 56.6 | Radical (R) | 2013-12-14 | 2013-12-20 | Etoposide + Ifosfamide (3 days) | N | N | 280027858 | ETOPOSIDE + IFOSFAMIDE |
| 280008517 | 280005717 | null | null | Curative (C) | null | 2015-07-24 | Cyclophosphamide oral | N | N | 280027862 | CYCLOPHOSPHAMIDE |
| 280008518 | 280005718 | null | 139.8 | Neo-adjuvant (N) | null | 2018-10-07 | Doxorubicin + Olaratumab | null | null | 280027865 | DOXORUBICIN + OLARATUMAB |
| 280008519 | 280005719 | 1.6 | 50.3 | Adjuvant (A) | 2016-07-30 | 2016-07-31 | VAC | 2 | N | 280027865 | CAV |
| 280008520 | 280005719 | 1.65 | 50 | Palliative (P) | 2016-11-05 | 2016-11-17 | Doxorubicin + Ifosfamide | N | N | 280027865 | DOXORUBICIN + IFOSFAMIDE |
| 280008521 | 280005721 | null | 60.9 | Adjuvant (A) | 2017-01-15 | 2017-01-16 | Gemcitabine day 1&8 | 02 | N | 280027877 | GEMCITABINE |
| 280008522 | 280005721 | 1.62 | 94.7 | Neo-adjuvant (N) | 2012-08-09 | 2013-10-20 | Cisplatin + Gemcitabine (D 1 & 8) | N | N | 280027877 | CISPLATIN + GEMCITABINE |
| 280008523 | 280005724 | 1.72 | 72.1 | Palliative (P) | 2018-05-25 | 2018-06-14 | Carboplatin + Paclitaxel (3 weekly) | N | N | 280027881 | CARBOPLATIN + PACLITAXEL |
| 280008524 | 280005725 | 1.66 | 52.8 | Neo-adjuvant (N) | 2016-05-06 | 2016-10-16 | Doxorubicin + Ifosfamide | N | N | 280027889 | DOXORUBICIN + IFOSFAMIDE |
| 280008525 | 280005725 | 1.58 | 64 | Adjuvant (A) | null | 2019-01-02 | CISPLATIN + FLUOROURACIL | N | N | 280027889 | CISPLATIN + FLUOROURACIL |
| 280008526 | 280005728 | null | null | Palliative (P) | 2014-07-06 | 2014-07-25 | CAV | N | N | 280027901 | CAV |
| 280008527 | 280005729 | null | 63.6 | Adjuvant (A) | 2019-03-11 | 2019-03-11 | Cyclophosphamide oral | N | N | 280027903 | CYCLOPHOSPHAMIDE |
| 280008528 | 280005729 | 1.82 | null | Neo-adjuvant (N) | 2018-05-05 | 2018-05-27 | FLUOROURACIL + IRINOTECAN | N | N | 280027903 | IRINOTECAN + MDG |
| 280008529 | 280005731 | 1.73 | 65 | Palliative (P) | 2016-09-24 | 2016-09-26 | CISPLATIN + FLUOROURACIL | 02 | null | 280027907 | CISPLATIN + FLUOROURACIL |
| 280008530 | 280005731 | 1.73 | 62.2 | Palliative (P) | 2015-12-11 | 2015-12-19 | CARBOPLATIN + ETOPOSIDE | N | N | 280027907 | CARBOPLATIN + ETOPOSIDE |
| 280008531 | 280005732 | 1.82 | 70 | Neo-adjuvant (N) | 2013-10-30 | 2013-11-05 | DE-ESCALATE TRIAL | null | null | 280027908 | DE-ESCALATE TRIAL |
| 280008532 | 280005732 | 1.88 | null | Palliative (P) | 2016-02-28 | 2016-03-20 | CETUXIMAB + CISPLATIN + FU | N | N | 280027908 | CETUXIMAB + CISPLATIN + FU |
| 280008533 | 280005734 | 1.69 | 97 | Palliative (P) | 2017-02-21 | 2017-03-07 | DOXORUBICIN + IFOSFAMIDE | 02 | N | 280027914 | DOXORUBICIN + IFOSFAMIDE |
| 280008534 | 280005735 | 1.77 | 64.3 | Palliative (P) | 2015-05-08 | 2015-09-19 | Oxaliplatin + Modified de Gramont | N | N | 280027922 | OXALIPLATIN + MDG |
| 280008535 | 280005736 | 1.79 | 75.7 | Adjuvant (A) | 2013-03-22 | 2013-03-28 | Cetuximab+Cisplatin+FU (> Cycle 2) | 02 | N | 280027926 | CETUXIMAB + CISPLATIN + FU |
| 280008536 | 280005740 | 1.6 | 70.6 | Palliative (P) | 2014-06-28 | 2014-08-03 | DE-ESCALATE TRIAL | N | N | 280027926 | DE-ESCALATE TRIAL |
| 280008537 | 280005742 | 1.65 | 69 | Neo-adjuvant (N) | 2014-10-09 | 2014-10-09 | Doxorubicin + Olaratumab | 02 | N | 280027929 | DOXORUBICIN + OLARATUMAB |
| 280008538 | 280005742 | 1.84 | null | Curative (C) | null | 2018-04-17 | EURO-EWING | null | null | 280027929 | EURO-EWING |
| 280008539 | 280009012 | 1.6 | null | Adjuvant (A) | 2016-06-23 | 2016-07-15 | VAI (Ifos 3g/m2) | 02 | N | 280027931 | IRINOTECAN + MDG |
| 280008540 | 280009013 | null | 101 | Neo-adjuvant (N) | 2014-10-08 | 2014-10-24 | Oxaliplatin + Modified de Gramont | N | N | 280027948 | OXALIPLATIN + MDG |
| 280008541 | 280010584 | 1.63 | 69.4 | Palliative (P) | null | 2014-09-22 | Irinotecan + Temozolomide | N | N | 280027955 | IRINOTECAN + TEMOZOLOMIDE |
| 280008542 | 280005745 | 1.5 | 55.5 | null | 2014-04-22 | 2014-04-25 | CYCLOPHOSPHAMIDE | 02 | null | 280027969 | CYCLOPHOSPHAMIDE |
| 280008543 | 280009014 | null | 102.7 | Not known (9) | 2013-07-28 | 2013-07-29 | EW EuroEwing 99 : VIDE | N | N | 280027969 | EURO-EWING |
| 280008544 | 280005749 | 0 | 115.9 | Neo-adjuvant (N) | 2013-06-20 | 2013-06-28 | CISPLATIN + FLUOROURACIL | N | N | 280027972 | CISPLATIN + FLUOROURACIL |
| 280008545 | 280005750 | null | 63.4 | Curative (C) | 2013-03-19 | 2013-10-22 | Carboplatin + Etoposide IV 3 day | N | N | 280027973 | CARBOPLATIN + ETOPOSIDE |
| 280008546 | 280005750 | 1.61 | 95 | Palliative (P) | 2017-10-12 | 2017-10-15 | Carboplatin + Etoposide iv&po | N | N | 280027973 | CARBOPLATIN + ETOPOSIDE |
| 280008547 | 280005751 | 1.72 | 96.3 | Neo-adjuvant (N) | 2017-05-27 | 2017-06-06 | EW EuroEwing 99 : VIDE | N | N | 280027975 | EURO-EWING |
| 280008548 | 280005752 | 1.7 | 73.4 | Adjuvant (A) | 2018-09-19 | 2018-10-11 | CISPLATIN + FLUOROURACIL | N | N | 280027976 | CISPLATIN + FLUOROURACIL |
| 280008549 | 280009016 | 1.73 | 67.9 | Palliative (P) | 2017-12-01 | 2017-12-01 | Cisplatin + Gemcitabine (D 1 & 8) | 02 | N | 280027977 | CISPLATIN + GEMCITABINE |
| 280008550 | 280009016 | 1.82 | 64.8 | Palliative (P) | 2016-05-07 | 2016-06-16 | EW Rel rEECur Irinotecan/Temozolomide | 02 | N | 280027977 | VAI |
| 280008551 | 280005753 | null | null | Palliative (P) | 2015-03-29 | 2015-04-08 | Etoposide + Ifosfamide (3 days) | N | N | 280027992 | ETOPOSIDE + IFOSFAMIDE |
| 280008552 | 280009017 | 1.65 | 73 | Adjuvant (A) | 2016-07-01 | 2016-07-19 | Cisplatin + Gemcitabine (D 1 & 8) | N | N | 280027992 | CISPLATIN + GEMCITABINE |
| 280008553 | 280009017 | 1.64 | 56.4 | Palliative (P) | 2016-06-20 | 2016-07-25 | Doxorubicin + Ifosfamide | N | N | 280027992 | DOXORUBICIN + IFOSFAMIDE |
| 280008554 | 280005756 | 1.55 | 69.7 | Palliative (P) | 2017-11-11 | 2017-12-14 | GEMCITABINE | N | N | 280028006 | GEMCITABINE |